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A B S T R A C T
Purpose
Prostate-specific antigen screening has led to enormous overtreatment of prostate cancer
because of the inability to distinguish potentially lethal disease at diagnosis. We reasoned that by
identifying an mRNA signature of Gleason grade, the best predictor of prognosis, we could
improve prediction of lethal disease among men with moderate Gleason 7 tumors, the most
common grade, and the most indeterminate in terms of prognosis.
Patients and Methods
Using the complementary DNA–mediated annealing, selection, extension, and ligation assay, we
measured the mRNA expression of 6,100 genes in prostate tumor tissue in the Swedish Watchful
Waiting cohort (n  358) and Physicians’ Health Study (PHS; n  109). We developed an mRNA
signature of Gleason grade comparing individuals with Gleason  6 to those with Gleason  8
tumors and applied the model among patients with Gleason 7 to discriminate lethal cases.
Results
We built a 157-gene signature using the Swedish data that predicted Gleason with low
misclassification (area under the curve [AUC]  0.91); when this signature was tested in the
PHS, the discriminatory ability remained high (AUC  0.94). In men with Gleason 7 tumors,
who were excluded from the model building, the signature significantly improved the
prediction of lethal disease beyond knowing whether the Gleason score was 4  3 or 3  4
(P  .006).
Conclusion
Our expression signature and the genes identified may improve our understanding of the
de-differentiation process of prostate tumors. Additionally, the signature may have clinical
applications among men with Gleason 7, by further estimating their risk of lethal prostate cancer
and thereby guiding therapy decisions to improve outcomes and reduce overtreatment.
J Clin Oncol 29:2391-2396. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Widespread use of prostate-specific antigen levels
for screening has led to a large increase in the inci-
dence of diagnosed prostate cancer and its treat-
ment.1 The overtreatment of prostate cancer is
widely recognized; recent randomized trial data sug-
gest that 48 menmust be treated to prevent a single
prostate cancer–specific death.2 A principal diffi-
culty in preventing overtreatment is our current in-
ability to distinguish at diagnosis with sufficient
confidence the men who will have an indolent
course of disease from those who have aggressive
disease. With more than 200,000 cases of prostate
cancer diagnosed3 and 168,000 prostatectomies4
each year in theUnited States, there is an acute need
to improve the ability to distinguish potentially le-
thal fromindolentdisease. Several groups, including
our own, have used mRNA expression profiling in
an attempt to construct a molecular signature of
lethal disease.5,6 In a variety of analyses, our group
developed signatures that predicted lethal disease
with a high degree of statistical significance but did
not substantially improve on models that included
known clinical predictors.5
Apart from stage, currently the strongest pre-
dictor of lethal prostate cancer is Gleason grade,7 a
measure of the degree of differentiation of prostate
tumor cells; the sum of the primary (predominant)
Gleason pattern (1 to 5) and the secondary pattern
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(1 to 5) is the Gleason score, which ranges from 2 to 10. In a study
using re-reviewed Gleason score from prostatectomy specimens,
those with a Gleason score of 8 had a hazard of lethal cancer (dying
from prostate cancer or developing distant metastases) that was 7.4
(95% CI, 2.5 to 22) times higher than those with Gleason 3  4;
patientswithaGleasonscoreof9 to10hadanevenhigher riskof lethal
cancer (hazard ratio, 19.1; 95%CI, 7.4 to 49.7).8 Currently,mostmen
presentwith apparently low-risk disease,with low tumor volume, and
with intermediate Gleason scores of 6 or 7.
SinceGleasongrade is such apowerful predictor of lethal disease,
we sought an alternative approach to outcome prediction. We rea-
soned that amolecular signature that discriminates poorly fromwell-
differentiated tumors defined by Gleason grade might improve
predictionof lethaldisease andprovide insight into thebiologicmech-
anisms underlying the strong relation of Gleason grade and dis-
ease progression.
Our work builds on previous studies9-15 in which molecular
signatures and pathways based on mRNA expression can distinguish
tumors according to Gleason grade. However, these past studies were
based on small numbers of patientswith prostate cancer, themethods
and signatures from one study are usually not replicated in another
and, importantly, they were not examined with respect to lethal out-
comes. In this study, we apply complementary analytic methods to
develop andvalidate anmRNAsignature todistinguishhigh from low
Gleason scores in two large, well-characterized cohorts: the Swedish
Watchful Waiting Cohort16-18 and the Physicians’ Health Study
(PHS).19,20 We then applied the results to determine whether the
signature could improve the prediction of lethal outcomes in men
with Gleason grade 7.
PATIENTS AND METHODS
Study Populations
The expression profiling data in this study were part of a project to
identifymolecular signatures of lethal and indolent prostate cancer and there-
fore included men who died from prostate cancer during follow-up (lethal
prostate cancer) or who survived at least 10 years after diagnosis (men with
indolent prostate cancer).5
Swedish Cohort
The population-based Swedish Watchful Waiting cohort consisted of
men diagnosed with incidental prostate cancer discovered through transure-
thral resection of the prostate (TURP) or adenoma enucleation (ie, stage
T1a-b) in the Uppsala-O¨rebro (1977-1994) and South East (1987-1999)
Health Care Regions of Sweden.16-18 Eligible patients were identified through
population-based prostate cancer databases. In accordance with prevailing
standards, patients were followed expectantly. No prostate-specific antigen
screening programs were then in place. The archival TURP specimens were
identified, and we included in the expression array patients with high-density
tumor regions (more than 90% tumor cells) and high-quality expression data
(n 358).
PHS
We included samples from men with histologically confirmed prostate
cancerwhowereparticipants in thePHS,19,20 a randomized trial of aspirin and
micronutrients in theprimarypreventionof cardiovasculardisease andcancer
among healthy US physicians. We have developed an archival repository of
tumor specimens from radical prostatectomy (RP) or TURP. For the expres-
sion profiling, we selected 116 (RP, n  102; TURP, n  14) patients with
high-density tumor area and includedonly thosewith high-quality expression
data in this analysis (n 109).
Gleason Grade Re-Review
We conducted a standardized review of the original hematoxylin and
eosin slides from referring hospitals and assigned a primary and secondary
Gleason grade.8 The review was conducted blinded to the original pathology
reports and any clinical data.
RNA Extraction and Profiling
A pathologist identified regions that were more than 90% tumor. Cores
were taken and deparaffinized; then RNA was extracted as previously de-
scribed.21 Four complementary DNA–mediated annealing, selection, exten-
sion, and ligation assay panels were designed for the Illumina platform
(Illumina; SanDiego,CA) for thediscoveryofmolecular signatures relevant to
prostate cancer, as previously described.21 The final array consisted of 6,100
genes. The annealing, selection, extension, and ligation assay was found to be
well-suited for formalin-fixed tissue22 and provides good correlation with
other standardmethods, such as quantitative reverse transcriptase polymerase
chain reaction (qRT-PCR).
Quality assessment was performed assuming a log-normal distribution
of 27control probes present within. We compared each gene measurement
with this negative control distribution, considering a gene “present” if its
expression level was above the 95th percentile. For each sample, we computed
the proportion of present genes. We excluded poor-quality samples with less
than55%presentmeasurements. The remaining rawdatawerenormalizedby
using a cubic spline algorithm. This procedure was adapted from Hoshida
et al.23
Statistical Analysis
We compared men with both Gleason patterns  3 (“Gleason  6”)
with men who had both patterns  4 (“Gleason  8”) to provide a sharp
contrast betweenhighand lowGleason scores, leavingoutmenwithGleason7
for later testing (see below).
First, in each cohort, we performed a t test for each of the 6,100 genes
to distinguish low grade from high grade. We determined whether the top
genes among those in the Swedish cohortwere enriched among the those in
the PHS by cross classifying genes according to whether or not they were in
the top 5%, 10%, 15%, 20%, or 25% of each, calculating a 2 test statistic
for each 2  2 table, and taking the largest of these; the P value was
calculated by permutation.
Pooling the cohorts, we ran a gene set enrichment analysis24,25 using 440
prespecifiedpathways fromtheBroad Institute’s curatedgene sets26 to identify
pathways enriched in either the high- or low-grade tumors.
We used the prediction analysis of microarrays (PAM) R package27 to
construct and validate a model predicting high-grade cancer. This method is
an adaptation of a nearest neighbor classificationmethod that considersmod-
els with different numbers of genes. First, we restricted our analysis to the
Swedishdata set (ie, the trainingdata set).We selected anoptimalmodel in the
Swedish data by considering cross-validated prediction error and parsimony.
Then we applied this model to the validation data set (PHS) and observed the
misclassification.Wevisualized the differences in expressionpatterns between
the twoGleason phenotypes by plotting individuals’ scores along the first two
principal components of the genes in thismodel, labeled by phenotype.Wefit
logistic regression models predicting lethal prostate cancer from these two
principal components, among theGleason6and theGleason8 separately
to see whether overall differences in expression patterns correlated with le-
thal outcomes.
Finally, we calculated the model’s predicted probabilities for poorly
versus well-differentiated tumors for men with Gleason 7 tumors, who were
not included in the training or validation sets. We sought to determine the
model’s ability to discriminate Gleason 4  3 from 3  4 and whether the
molecular signature could improve prediction of lethal outcomes amongmen
with Gleason 7 using logistic regression.
All analyses were performedwith SAS 9.1 (SAS Institute, Cary, NC) and
the R package. This study is compliant with ethical committees at the Univer-
sity of O¨rebro and the institutional review board of Partners HealthCare.
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RESULTS
Clinical characteristics of the Swedish and PHS cohorts are pro-
vided in Table 1, and further details of each Gleason phenotype are
provided in Table 2. All of the patients in the Swedish cohort were
diagnosed from TURP or adenoma enucleation samples and thus
were staged either T1a ( 5% cancer) or T1b, depending on the
proportion of the tissue that was cancerous. The majority of PHS
patients (65%) had T1 or T2 tumors.
To improvecontrastofGleasonphenotypes in initial analyses,we
compared tumors with Gleason score  6 to those with Gleason
score  8. In the Swedish cohort, after Bonferroni correction for
multiple comparisons, 107 genes remained significant at the family-
wise 0.05 level (Appendix Table A1, online only) after 6,100 t tests
comparing lowGleason score with highGleason score; 784 genes had
a false discovery rate (FDR) less than 0.05. In the PHS, a smaller data
set of two genes were significant at the family-wise 0.05 level (Appen-
dixTableA2,onlineonly); 74geneshadanFDRless than0.05.The top
10% of genes in the Swedish cohort were enriched in the top 10% of
genes in the PHS cohort (P .001).
Pooling the cohorts, we applied a gene set enrichment analysis
(GSEA)24,25 to identify pathways commonly enriched among high-
gradeor low-gradecancers.We identified15pathways fromtheGSEA
database that were enriched among the high-grade tumors and three
pathways that were enriched among the low-grade tumors with an
FDR less than0.10 (Table 3).The enrichedpathways in thehigh-grade
tumors are involved in the cell cycle, PI3K/AKT pathway, pyrimidine
metabolism, and one-carbon folate, while pathways in the low-grade
tumors were related to propanoate metabolism.
Separating the cohorts again, we built and tested a signature to
predict high and low Gleason grades using PAM.We built the model
in the Swedish data set (the training set) and estimated the level of
misclassification of Gleason pattern using cross validation. The most
parsimonious model that minimized misclassification contained 157
genes (Appendix Table A3, online only) and had an average misclas-
sification rate of 17%of the twoGleason classes in the Swedish cohort
(Appendix Fig A1, online only). We further examined the predictive
ability of the genes in this set by measuring the area under the
[concentration-time] curve (AUC) which was 0.91 (95% CI, 0.87 to
0.95; Fig 1A). When our model from PAMwas applied to the testing
set (PHS data), the average misclassification rate was 16% in the two
groups, and theAUCwas0.94 (95%CI,0.86 to0.99;Fig1B).Whenwe
built a signature using PAM on the PHS data and applied it to the
Swedish cohort, the results formisclassification andAUCwere similar
(data not shown).
Weexaminedtheoverall variability inexpressionof the157genes
in the signature. Pooling the two cohorts, we calculated the first two
principal components of the 157 genes in the model (Fig 2). The
tumorswithGleason6patterns seemtohave fairly consistentvalues
of the first principal component, suggesting more homogeneity in
expression of genes. In contrast, those with Gleason 8 tumors have
amore varied expression pattern.We observed that among individu-
als withGleason 8, as they are further to the right of Figure 2 (more
Table 1. Clinical Characteristics of Prostate Cancer Patients in the
Swedish and PHS Cohorts
Characteristic
PHS Cohort
(n  109)
Swedish
Cohort
(n  358)
No. % No. %
Years of diagnosis 1983-2003 1987-1999
Gleason score
5 0 0 3 1
6 12 11 106 30
3  4 34 31 85 24
4  3 30 28 74 20
8 18 16 22 6
9 12 11 56 16
10 3 3 12 3
Clinical outcomes
Lethal cases 30 28 171 48
Stage
T1a-N0-MX 110 31
T1b-N0-MX 241 69
T1/T2 70 65
T3 28 26
T4/N1/M1 10 9
Missing 1 7
Age at diagnosis, years (mean  SD) 67.3  7 73.4  7
Abbreviations: PHS, Physicians’ Health Study; SD, standard deviation.
Table 2. Clinical Characteristics of Patients in the Swedish and PHS Cohorts, Stratified by Gleason Category
Characteristic Total No. of Patients
Long-Term Survivors
Patients With
Lethal Cancer
Age at Diagnosis
(mean years  SD)No. % No. %
Swedish cohort
Gleason  6 109 88 81 21 19 71.6  7
Gleason  8 89 14 16 75 84 74.6  7
Gleason 3  4 85 52 61 33 39 72.8  7
Gleason 4  3 74 33 45 41 55 75.3  7
PHS cohort
Gleason  6 12 12 100 0 0 64.4  4
Gleason  8 33 11 33 22 67 70.4  8
Gleason 3  4 34 33 97 1 3 66.1  6
Gleason 4  3 30 23 77 7 23 66.4  7
Abbreviations: PHS, Physicians’ Health Study; SD, standard deviation.
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like the Gleason 6), their risk of lethal prostate cancer significantly
decreases (P .03).
We then applied the 157-gene signature to the 159 men in the
Swedish cohort and the 64men in the PHS with Gleason 7 tumors to
see whether those with Gleason 4 3 would be more likely classified
by the signature as Gleason 8 than those with Gleason 3 4. The
predictive ability to discriminate 4 3 from 3 4 cancer was statis-
tically significant but of modest magnitude; the AUC for this model
was 0.60 (95%CI, 0.53 to 0.68).
However, the 157-gene signature improved prediction of lethal-
ity among the men with Gleason 7, a group with mixed predictive
ability.We used logistic regression to predict prostate cancer–specific
death among the Swedish men with Gleason 7; we included in the
model theGleason score (4 3 v 3 4) and the estimatedprobability
of being high grade from the 157-gene signature. We found that the
probability of being high grade from the gene signature statistically
significantly predicted lethal prostate cancer (odds ratio [OR], 1.46;
95%CI, 1.09 to1.95per33%increase inpredictedprobabilityofbeing
high grade); the gene signature provided a significant improvement
over themodelwithGleasonscorealone(likelihoodratio testP .01).
In an independent assessment in thePHScohort, theORwas identical
but the association was nonsignificant (OR, 1.44; 95% CI, 0.57 to
3.68), reflecting the smaller sample size. Combining the men with
Gleason 7 from the two cohorts, we found that the OR was 1.47
(95% CI, 1.11 to 1.94) for a 33% increase in the model prediction.
This model, which included an indicator of Gleason score (4 3 v
Table 3. Gene Pathways Enriched in High-Grade (Gleason  8) or Low-Grade (Gleason  6) Tumors, Based on Gene Set Enrichment Analysis Using Molecular
Signature Databases From the Broad Institute
Pathways Enriched in High-Grade Tumors Pathway Description Pathways Enriched in Low-Grade Tumors
CELL_CYCLE_KEGG HSA00640_PROPANOATE_METABOLISM
HSA04110_CELL_CYCLE PROPANOATE_METABOLISM
G1_TO_S_CELL_CYCLE_REACTOME HSA00410_BETA_ALANINE_METABOLISM
DNA_REPLICATION_REACTOME
PTDINSPATHWAY PI3K phosphorylate inositol rings of
phosphoinositide lipids, influencing vesicle
trafficking, cell proliferation, and migration
GSK3PATHWAY Bacterial lipopolysaccharide activates AKT to
promote the survival and activation of
macrophages and inhibits Gsk3-beta to promote
beta-catenin accumulation in the nucleus
ST_GA13_PATHWAY G-alpha-13 influences the actin cytoskeleton and
activates protein kinase D, PI3K, and Pyk2
PYRIMIDINE_METABOLISM
HSA00240_PYRIMIDINE_METABOLISM
ONE_CARBON_POOL_BY_FOLATE
HSA00670_ONE_CARBON_POOL_BY_FOLATE
MRNA_PROCESSING_REACTOME
EPOPATHWAY Erythropoietin, which activates the MAPK
pathway, stimulates erythrocyte production and
is an effective treatment for anemia
HSA04330_NOTCH_SIGNALING_PATHWAY
HSA04120_UBIQUITIN_MEDIATED_PROTEOLYSIS
NOTE. False discovery rate  0.1. Lines divide pathways into clusters based on large numbers of overlapping genes.
Abbreviation: PI3K, phosphoinositide 3 kinase.
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Fig 1. Receiver operating characteristic
(ROC) curves for the 157-gene signature
developed with prediction analysis of mi-
croarrays. (A) ROC curve for the model
built in the Swedish cohort for Gleason 
6 and Gleason  8, applied to those same
men. (B) ROC curve for the model built in
the Swedish cohort applied to men in the
Physicians’ Health Study with Gleason 
6 and Gleason  8. In each plot, the gold
dot is where misclassification rates are ap-
proximately equal in the two groups.
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3 4), an indicator of cohort, and the predicted probabilities from
our model, was significantly improved over a model with just
Gleason score and cohort (likelihood ratio test P .006). Adding
age at diagnosis to themodel does not change the predictive ability
(OR, 1.48; P .006).
We compared the frequency of lethal cancers by tertiles of our
predicted probability. One third of the men received predicted prob-
abilities between 0 and 0.16, one third between 0.16 and 0.73, and one
third between 0.73 and 1. Twenty-nine percent of the men in the
lowest tertilediedofprostate cancer comparedwith36%of themen in
the middle tertile and 45% of the men in the upper tertile; thus, the
difference in frequencyofdeathbetween the lowest andhighest tertiles
was 16%.
DISCUSSION
Gleason grade is one of the strongest clinical predictors of prostate
cancer progression. Men with low-grade Gleason 6 tumors, have a
lowmetastatic potential, even in the absence of therapy28; in contrast,
menwith high-gradeGleason 8 to 10 tumors have a high likelihoodof
progression, even with curative therapies. There is mixed discrimina-
tion among themendiagnosedwithGleason7 tumors,who represent
a substantial proportionofprostate cancers diagnosed currently in the
United States and other western countries. Improving risk prediction
among patients with Gleason 7, as well as understanding the mecha-
nisms leading to prostate tumor differentiation, is paramount to un-
derstanding this heterogeneous disease.
In this large studywith long-term follow-up,we identified sets of
genes that differentiate between low and high Gleason grade in a
Swedish and a US cohort of men with prostate cancer. Additionally,
we used a GSEA to identify the key pathways that go awry in the
de-differentiation process in prostate cancer. Finally, we developed a
Gleason signature that was significantly predictive of lethal prostate
cancer among themenwithGleason 7, independent of 3 4 or 4 3
status. While this result warrants further study, it provides additional
proof of principle for the utility of expressionprofiling inunderstand-
ing the clinical heterogeneity of prostate cancer. This signature may
have direct clinical application for men diagnosed with Gleason 7
tumors, the largest category of patients, and the one that poses the
greatest challenges for treatment decision.
An additional finding was that, when examining the first two
principal components of the genes in our 157-gene model, there
was more homogeneity in patterns of expression among patients
with Gleason  6 than among those with Gleason  8. This is
consistent with the findings of True et al12 that Gleason pattern 3
alterations are fairly similar, while pattern 4 and 5 tumors aremore
diverse, even occasionally having features of pattern 3.We consider
this analogous to the first line of Tolstoy’s Anna Karenina: “All
happy families are alike; each unhappy family is unhappy in its own
way.”29 Minor loss of differentiation may occur in the same path-
ways and genes in most individuals, but greater loss of normal
structure can occur in many different ways. We noted that as
Gleason 8 tumors lookedmore like Gleason 6 tumors, the risk
of lethal prostate cancer significantly decreased.
While we could reliably distinguish Gleason 6 from Gleason
 8 in both our training and our test data sets, the signature did not
discriminate well betweenGleason 3 4 and 4 3. As we and others
have shown, outcomes in the clinically heterogeneous category of
Gleason 7 tumors can be further refined by determining the predom-
inant Gleason score.8,30-32 The inability to identify a gene signature
that distinguishes betweenGleason 3 4 and 4 3may be due to the
way the tissues were collected—the Gleason grade of the exact cores
used for mRNA extraction may not perfectly match the overall grade
assigned to the patient. Therefore, the core from a Gleason score 7
could be Gleason grade 3, Gleason grade 4, or some combination of
the two patterns.
In a previous examination of these datasets, we noted that the
overall expression profiles for the Swedish and PHS samples differed
substantially, most likely because of the types of specimens used
(TURP for the Swedish cohort; 88%RP for thePHScohort).Ourdata
suggest that the genes that predict Gleason score are robust regardless
of the technique used for tissue collection, because we developed a
signature in TURP samples and validated it in mostly RP specimens.
This study is larger than previous studies that address this ques-
tion, includes centrally reviewedand standardizedGleason scoremea-
surements, and is able to examine the association of the developed
signaturewith lethal prostate cancer.We examined only a subset of all
knowngenes, so there couldbemanyother genes that predictGleason
score. However, the 6,100 genes were selected specifically for possible
involvement in prostate cancer, so they may capture a large propor-
tion of the variation.
Our results provide many biologic hypotheses for genes and
pathways that may underlie the differentiation of prostate cancer
tissue.Onepathwaywe identified throughGSEA that involved the cell
cycle was recently reported to be themodulemost strongly associated
with Gleason in lymphoblastoid cell lines from patients with prostate
cancer.33 SinceGleason score is a strong predictor of outcome, the path-
ways identifiedheremay be important in disease progression aswell.
The expression signature identified may enhance our under-
standing of the de-differentiation process of prostate tumors andmay
have clinical applications for men with Gleason 7 tumors, improving
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Fig 2. The first two principal components of the 157-gene model in the Swedish
and Physicians’ Health Study data sets, comparing men with Gleason  6
(Both  3) and men with Gleason  8 (Both  4).
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the prediction of lethal cancer and thereby guiding therapy decisions.
The use of these prediction tools, or perhaps further refined versions,
is likely to improve outcomes while reducing the overtreatment of
indolent disease.
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CORRECTIONS
Author Corrections
The December 15, 2003 article by Pels et al, entitled, “Primary
Central Nervous System Lymphoma: Results of a Pilot and Phase II
StudyofSystemicandIntraventricularChemotherapyWithDeferred
Radiotherapy”(JClinOncol21:4489-4495,2003),containedanerror.
In Table 1, the following footnote was inadvertently omitted:
“Reproduced from J Neurol Neurosurg Psych (Schlegel et al)
71:118-122, 2001, with permission from BMJ Publishing Group Ltd.”
The authors apologize for the mistake.
DOI: 10.1200/JCO.2012.44.4109; published June 20, 2012
■ ■ ■
The June 10, 2011 article by Penney et al, entitled,
“mRNA Expression Signature of Gleason Grade Predicts
Lethal Prostate Cancer” (J Clin Oncol 29:2391-2396, 2011),
contained an error.
The study by Sboner et al, cited as reference number 5,
referred to a microarray dataset of the Swedish cohort that
represented only a subset of the men with high- and low-grade
cancer studied. Thus, the authors have now made an updated
data file accessible through the Gene Expression Omnibus
(GEO), accession number GSE37663. This should be noted in
the last paragraph of the Patients and Methods section, under
Statistical Analysis, as follows:
“All analyses were performed with SAS 9.1 (SAS Institute,
Cary, NC) and the R package. The Swedish 6K microarray
dataset for discoverywork is available at theGene Expression
Omnibus under accession number GSE37663. This study is
compliant with ethical committees at the University of Örebro
and the institutional review board of Partners HealthCare.”
The authors apologize for the omission.
DOI: 10.1200/JCO.2012.44.4117; published June 20, 2012
■ ■ ■
The December 20, 2011 article by Breuer et al, entitled,
“Medical Oncologists’ Attitudes and Practice in Cancer Pain
Management: A National Survey” (J Clin Oncol 29:4769-4775,
2011), contained errors.
In Table 2, the following footnote incorrectly described
unacceptable responses and should have read:
“†Given practice variation, acceptable responses were
considered a and/or c and/or d, with or without g, with no
other choice checked.Unacceptable responses were b, dose too
low; e, dose too low and no reason for rotation; and g alone; and
f, no evidence of efficacy; 291 responders (60%) checked an
unacceptable response.”
The authors apologize for the mistakes.
DOI: 10.1200/JCO.2012.44.4133; published June 20, 2012
■ ■ ■
The April 20, 2012 article by Finkelman et al, entitled,
“Breast and Ovarian Cancer Risk and Risk Reduction in Jewish
BRCA1/2 Mutation Carriers” (J Clin Oncol 30:1321-1328,
2012), contained an error.
The following study support was inadvertently omitted
and should have been acknowledged in the sidebar of the
article:
“City of Hope Clinical Cancer Genetics Community Net-
work and the Hereditary Cancer Research Registry, supported
in part by Award Number RC4CA153828 (PI: J.N. Weitzel)
from the National Cancer Institute and the Office of the Direc-
tor, National Institutes of Health.”
The authors apologize for the mistake.
DOI: 10.1200/JCO.2012.44.4158; published June 20, 2012
■ ■ ■
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